Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Rostafuroxin- Rostaquo

Drug Profile

Rostafuroxin- Rostaquo

Alternative Names: PST 2238

Latest Information Update: 14 Aug 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator sigma-tau SpA
  • Developer Rostaquo; sigma-tau SpA; Windtree Therapeutics
  • Class Androstanes; Antihypertensives; Furans; Small molecules
  • Mechanism of Action Adenosine triphosphatase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Hypertension

Most Recent Events

  • 11 Mar 2019 Rostafuroxin is still in phase II trials for Hypertension in Taiwan (NCT03217825)
  • 21 Dec 2018 Windtree Therapeutics merged with CVie Therapeutics to form Windtree Therapeutics
  • 18 Dec 2015 Phase-II clinical trials in Hypertension in Taiwan (PO) (CVT-CV-001)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top